AVITA Medical, Inc. reported its financial results for the second quarter of 2025, revealing a total revenue of $18.4 million, a 21% increase from $15.2 million in the same period last year. The growth was primarily driven by increased sales of the RECELL product line, which saw deeper penetration in customer accounts and the addition of new accounts for treating traumatic and surgical wounds. The company recorded a gross profit of $14.9 million, resulting in a gross margin of 81.2%, down from 86.1% in the prior year, attributed to volume discounts and a higher inventory reserve.
In terms of profitability, AVITA Medical reported a net loss of $9.9 million for the quarter, a significant improvement compared to a net loss of $15.4 million in the same quarter of 2024. The operating loss also decreased to $11.1 million from $15.6 million year-over-year, reflecting a reduction in total operating expenses, which fell by 9% to $26.1 million. The decrease in expenses was driven by lower sales and marketing costs, as well as general and administrative expenses, which were down 11% due to reduced salaries and stock-based compensation.
The company has made strategic advancements, including the full commercial launch of Cohealyx, a collagen-based dermal matrix, on April 1, 2025. This product is expected to complement the existing RECELL System and PermeaDerm offerings, enhancing AVITA's position in the wound care market. Additionally, the company has entered into significant agreements with Stedical Scientific, Inc. and Regenity Biosciences, which will allow it to expand its product offerings and market reach.
Operationally, AVITA Medical's cash and cash equivalents stood at $12.2 million as of June 30, 2025, alongside $3.5 million in marketable securities. The company has faced challenges in maintaining compliance with its credit facility's minimum cash balance covenant, leading to substantial doubt about its ability to continue as a going concern. To address this, AVITA is actively exploring additional funding options, including equity financing and debt issuance. The company has amended its credit agreement to adjust revenue covenants, reflecting its ongoing efforts to manage its financial obligations while pursuing growth opportunities.
Looking ahead, AVITA Medical aims to increase market penetration in U.S. burn centers and expand the adoption of its RECELL portfolio for various wound treatments. The company is also focused on obtaining CE mark approval for RECELL GO to facilitate entry into European markets. Despite the current macroeconomic challenges, including supply chain issues and changes in reimbursement policies, AVITA Medical remains committed to driving revenue growth and achieving operational profitability in the coming quarters.
About AVITA Medical, Inc.
AVITA Medical develops and commercializes advanced acute wound care solutions centered on its patented RECELL technology, which creates autologous skin cell suspensions to accelerate healing of burns, full-thickness skin defects, and vitiligo. The company’s product portfolio includes RECELL devices and complementary wound care matrices like PermeaDerm and Cohealyx. Serving burn and trauma centers primarily in the U.S. and select international markets, AVITA leverages proprietary technology, regulatory approvals, and clinical evidence to improve patient outcomes and reduce treatment costs.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.